Mycolactone is a polyketide-derived macrolide produced and secreted by a group of very closely related pathogenic mycobacteria species including M. ulcerans, M. liflandii (an unofficial designation), M. pseudoshottsii, and some strains of M. marinum. These mycobacteria are collectively referred to as mycolactone-producing mycobacteria or MPM. In humans, mycolactone is the toxin responsible for Buruli ulcers, doing so by damaging tissues and inhibiting the immune response.
History
Early observations In the 1960s, pathologists studying Buruli ulcer in Uganda noted extensive tissue necrosis with very little inflammation extending beyond bacterial clusters, suggesting secretion of a diffusible cytotoxin by Mycobacterium ulcerans.
Discovery and characterization In 1999, George and colleagues purified this factor from alcohol-soluble lipids and identified a 12-membered macrolactone with two polyketide side chains, naming it mycolactone (from its mycobacterial origin and macrolactone structure). It was the first polyketide macrolide isolated from a mycobacterium and the first identified polyketide virulence factor of a human pathogen. In 2002, the total synthesis of the molecule was done by Song et al. and enabled the creation of synthetic variants for laboratory study.
Evolving understanding (2000s - Present) Research in the early 2000s identified that the genetic instructions for mycolactone reside on a giant virulence plasmid, pMUM001. Researchers also discovered that naturally occurring mycolactone consists of several structural variants, primarily isomers A and B (Z/E at C4′–C5′), with absolute stereochemistry confirmed by total synthesis. Subsequent studies identified additional congeners (C–F and beyond) from strains of different geographic origins. Comparative genomics later showed all mycolactone producing mycobacteria derive from a common M. marinum like ancestor, now regarded as ecovars of M. ulcerans. The functional understanding of mycolactone shifted significantly in the 2010s. While initially viewed strictly as a necrotizing agent, it was discovered to be a potent inhibitor of the Sec61 translocon. By blocking this gateway, mycolactone prevents cells from translocating proteins into the endoplasmic reticulum, effectively "silencing" the host's immune signaling and contributing to the characteristic lack of pain (analgesia) in early lesions. More recently, in the 2010s and 2020s, this deep mechanistic knowledge has been translated into clinical tools. Researchers have developed highly sensitive diagnostic tests for Buruli ulcer and are even exploring modified, non-toxic versions of mycolactone as potential anti-inflammatory or pain-relief drugs.
Structure and reactivity
Molecular Architecture Mycolactone is a polyketide-derived lipid-like macrolide toxin. Its gross structure is composed of three distinct sectors:
The Macrolactone Core: A conserved 12-membered macrocyclic lactone ring (C1–C11). The Northern Side Chain: A short, invariant chain linked "core extension" comprising carbons C12–C20. The Southern Side Chain: A long, oxygen-linked (C5-O-linked) polyunsaturated fatty acid fragment (C1'–C16'). The "extended core" refers to the entire C1–C20 segment (with the carbonyl carbon of the lactone ester group as C1), while the southern side chain is a sensitive structure containing multiple double bonds and three stereogenic centers at C12', C13', and C15'.
Isomerism and Stereochemistry Naturally occurring mycolactone does not exist as a single static molecule. Instead, it forms as a dynamic 3:2 mixture of two geometric isomers: mycolactone A (the Z-isomer) and mycolactone B (the E-isomer). These isomers differ only in the configuration of the double bond at the C4'–C5' position of the southern side chain. While they exist in equilibrium, synthetic studies suggest that the B analog is significantly more cytotoxic, potentially serving as the primary virulence factor.
Physical Properties and Stability Due to its hydrophobic backbone and polar hydroxyl groups, mycolactone is amphiphilic, exhibiting surfactant-like and micelle-forming behavior in water. This structure gives it a high affinity for embedding itself into cellular membranes, where it disturbs lipid organization. The molecule is also highly unstable and sensitive to environmental factors: it is prone to photodegradation upon UV light exposure, it can thermally decompose even at –20 °C, and its central ester bond is easily broken down by metabolic processes.
Structure-Activity Relationship (SAR) Extensive studies of total synthesis have identified how structural modifications affect the toxin's biological potency. Collectively, pruning or simplifying the side chains in any significant way is generally unfavorable for biological activity. While the northern chain allows for some functionalization, such as the attachment of laboratory tracking tags (such as fluorescent dyes or biotin), the southern side chain remains the primary driver of mycolactone's cytotoxic and immunosuppressive effects.
Variants Five distinct, naturally occurring mycolactone structural variants have been described so far:
Mycolactone A/B (M. ulcerans from Africa, Malaysia, Japan) Mycolactone C (M. ulcerans from Australia) Mycolactone D (M. ulcerans from China) Mycolactone E (M. liflandii from Sub-Saharan Africa) Mycolactone F (M. pseudoshottsii and M. marinum from around the world) Mycolactone S1 and S2 (M. ulcerans from Africa, Malaysia, Japan)
Synthesis The production of mycolactone is studied through two lenses: biosynthesis, the natural process by which M. ulcerans assembles the toxin, and chemical synthesis, the laboratory methods developed by scientists to create pure samples for research.
Biosynthesis Mycolactone is produced by a specialized genetic "factory" located on the giant plasmid pMUM001. The synthesis is driven by Type I modular polyketide synthases (PKS). These are massive multi-domain enzymes (named MLSA1, MLSA2, and MLSB) that act like a molecular assembly line (5,13).
… excerpt ends here. Continue reading the full article.
